Major Breakthrough: Human Kidney Organoids Successfully Transplanted into Pig Kidney, Paving New Path for Regenerative Medicine
Release time:
2025-11-07
On October 21, 2025, researchers from the Catalan Institute of Bioengineering in Spain published a research paper in Nature Biomedical Engineering, announcing a critical advancement in the clinical application of organoid technology, marking a significant milestone for regenerative medicine and personalized healthcare.
Organoid technology holds broad prospects. Organoids cultivated from human pluripotent stem cells (hPSCs) can highly faithfully recapitulate key features of developing human organs, providing a platform for simulating human development and disease. However, the clinical application of organoid technology, such as in tissue regeneration and organ transplantation, faces numerous obstacles. Producing hPSC-derived organoids with scalability, consistency, and reproducibility is particularly challenging.
This study developed a scalable, reproducible, and economical method to generate human kidney organoids (hPSC-kidney organoids) from hPSCs using micro-aggregation and genetic engineering techniques, which can also be differentiated into various kidney cell types. Kidney organoids are three-dimensional structures grown in the laboratory from human stem cells. Although not complete organs, they replicate many key structures and functions, and can be used to study kidney development, test new drugs, and hold potential for repairing damaged kidney tissue or improving organs destined for transplantation.
The research team utilized various techniques, including single-cell RNA sequencing, and found that hPSC-kidney organoids exhibited transcriptional diversity and changes in cellular composition after cell-cell contact. They employed a normothermic mechanical perfusion method to perfuse the hPSC-kidney organoids into an isolated pig kidney, and then transplanted the pig kidney back into the same pig, confirming the successful in vivo transplantation of the hPSC-kidney organoids.
This represents the first successful integration of human kidney organoids with a living pig kidney connected to a normothermic perfusion machine and subsequent transplantation back into a pig. The team also assessed the immune response through multiple means, confirming the procedure's feasibility and effectiveness. At 24 and 48 hours post-transplantation, the hPSC-kidney organoids remained integrated and viable within the pig kidney tissue, did not trigger a significant immune response, and the transplanted pig kidney functioned normally without signs of damage or toxicity.
This breakthrough paves the way for clinical trials using hPSC-kidney organoids for ex vivo cell therapy. The long-term goal of the research team is to achieve organ regeneration or repair through cell therapy prior to transplantation, thereby reducing patient waiting times and increasing the number of healthy organs available for transplant. This study also marks a historic turning point for regenerative medicine, offering new avenues to address the global organ shortage crisis. Nonetheless, challenges remain in translating this from the laboratory to clinical application, including safety evaluation, technical standardization, and ethical considerations. However, with technological refinement and regulatory maturation, cell therapies based on organoids are expected to enter the clinical trial phase within the next 5 to 10 years.
Latest developments
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
According to the latest announcement from the International Society of Cryobiology, Professor Xu Yi from the School of Health Science and Engineering at the University of Shanghai for Science and Technology, and a member of the Yinfeng Cryomedicine Expert Committee, has been elected as a Board Governor of the Society for a three-year term (2026–2028). The election was conducted through a democratic vote by all members worldwide, with three new Board Governors elected. Professor Xu Yi is the only scholar from Asia elected to the Society’s Board of Governors this time and the third elected scholar from mainland China in the Society’s 60-year history.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
